A Phase 2a, Randomized, Double-blind, Placebo- and Naproxen Controlled, Parallel-group Study to Assess the Analgesic Efficacy of ASP7962 in Patients With Pain Due to Osteoarthritis of the Knee
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 02 Aug 2017
At a glance
- Drugs ASP 7962 (Primary) ; Naproxen
- Indications Osteoarthritis
- Focus Therapeutic Use
- Acronyms OAK
- Sponsors Astellas Pharma Europe Ltd
- 27 Jul 2017 Status changed from recruiting to active, no longer recruiting.
- 27 Feb 2017 Planned End Date changed from 1 Jun 2017 to 1 Sep 2017.
- 27 Feb 2017 Planned primary completion date changed from 1 May 2017 to 1 Aug 2017.